Overview of Relapsed/Refractory Multiple Myeloma
The expert panel provides an overview of relapsed/refractory multiple myeloma, with a focus on current therapeutic options and unmet needs in the treatment space.
EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?
EP: 2.Overview of Relapsed/Refractory Multiple Myeloma
EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM
EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM
EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab
EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma
EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities
EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management
EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma
EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma
This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Usmani distinguishes between relapsed and refractory multiple myeloma. Refractory disease progresses on therapy, whereas relapsed disease recurs after a treatment-free interval of at least 2 months. Management involves selecting optimal regimens based on patient and disease factors and prior treatment tolerance. If disease is triple-class refractory, options narrow but new targets such as BCMA and GPRC5D enable chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies. Two CAR T-cell products targeting BCMA are approved: idecabtagene vicleucel and ciltacabtagene autoleucel. Bispecifics include teclistamab and elranatamab.
Despite emerging treatments, unmet needs remain, including CAR T-cell accessibility, capacity for bispecific antibodies, managing renal dysfunction and frailty, post-BCMA progression, and high-risk cytogenetics.
Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
